Corporate Overview

September 2021

NASDAQ: GALT

www.galectintherapeutics.com

2021 Galectin Therapeutics | NASDAQ: GALT

For more information, see galectintherapeutics.com

Forward-looking statements

This presentation contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance and use words such as "may," "estimate," "could," "expect" and others. They are based on our current expectations and are subject to factors and uncertainties that could cause actual results to differ materially from those described in the statements.

These statements include those regarding potential therapeutic benefits of our drugs, expectations, plans and timelines related to our clinical trials, supporting activities, potential partnering opportunities and estimated spending for 2021 and beyond. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others, our trials and supporting CMC information may be impacted by COVID-19.

We may experience delays in our trials, which could include enrollment delays. Future phases or future clinical studies may not begin or produce positive results in a timely fashion, if at all, and could prove time consuming and costly. Plans regarding development, approval and marketing of any of our drugs are subject to change at any time based on the changing needs of our company as determined by management and regulatory agencies. Strategies and spending projections may change. We may be unsuccessful in developing partnerships with other companies or obtaining capital that would allow us to complete our clinical trials or further develop and/or fund any future studies or trials.

To date, we have incurred operating losses since our inception, and our future success may be impacted by our ability to manage costs and finance our continuing operations. For a discussion of additional factors impacting our business, see our Annual Report on Form 10-K for the year ended December 31, 2020, and our subsequent

filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent

events may cause our views to change, we disclaim any obligation to update forward-looking statements.

2

2021 Galectin Therapeutics | NASDAQ: GALT

For more information, see galectintherapeutics.com

Contents

  • Overview
  • NASH cirrhosis and belapectin
  • NASH-CXresults
  • NAVIGATE trial
  • Belapectin oncology data overview
  • Summary

3

2021 Galectin Therapeutics | NASDAQ: GALT

For more information, see galectintherapeutics.com

Galectin Overview

  • Conducting an adaptively-designed Phase 2b/3 trial of belapectin, a potent galectin-3 inhibitor, for the prevention of esophageal varices in NASH cirrhosis (NAVIGATE)
    ▪ First patient randomized August 2020
  • Belapectin is a novel galectin-3 inhibitor that targets macrophages (a key driver in cirrhosis) and may improve multiple fibrotic diseases
  • NASH market opportunity estimated to reach $35 - $40 billion/year by 20251
  • Belapectin efficacy observed in animal models and Phase 2 trial (NASH-CX)
  • NASH-CXin patients with compensated cirrhosis and portal hypertension demonstrated that belapectin prevented the development of new esophageal varices in a population with a high degree of clinical unmet need with no available therapies and few in development2
  • Belapectin in combination with PD-1 inhibitor showed encouraging clinical response rate in difficult to treat cancers (e.g. metastatic melanoma)
  • Belapectin has a robust IP portfolio
    • Composition of matter for complex carbohydrates and/or methods of use in treatment of fibrosis, in combination cancer immunotherapy and other indications
    • Patent applications filed for small molecule gal-3 inhibitors

4

1 Deutsche Bank "NASH - the next big global epidemic in 10 years?" July 14, 2014 2 Chalasani et al. Gastroenterol 2020

2021 Galectin Therapeutics | NASDAQ: GALT

For more information, see galectintherapeutics.com

Strong, experienced team

Joel Lewis, CEO and President

  • Over 22 years of executive management experience at Uline, Inc.; Century America LLC; Deloitte
  • Served on the Board of Directors since December 2017

Ben Carson, Sr., M.D., Senior Advisor

  • Responsible for to increasing awareness of Galectin, its ongoing Phase 2b/3 NAVIGATE clinical trial, and its continued research in combination with cancer immunotherapy
  • Assisting in the recruiting and formation of a scientific advisory committee and identifying potential strategic commercial partners

Dakshina Reddy, Executive Director, Regulatory Affairs

  • Over 22 years of experience in regulatory affairs and clinical research
  • Particular expertise in global regulatory, drug development, and regulatory life-cycle management strategies, having worked with the FDA, EMA, PMDA, and Health Canada
  • Previous position was Global Program Regulatory Director at Novartis

Harold H. Shlevin, Ph.D., Former CEO and President,

Consultant and Board Member

  • Over 35 years of relevant experience
  • Previous position was CEO of Solvay Pharmaceuticals

Pol F. Boudes, M.D., Chief Medical Officer

  • Over 25 years of experience in clinical drug development in immunology, endocrine, metabolic, orphan, and liver-related diseases, and he has contributed to the approval of multiple drugs, both in the US and globally, across a variety of therapeutic indications.
  • Previous position was CMO of CymaBay Therapeutics

Jack W. Callicutt, CFO

  • Over 28 years of relevant experience
  • Reach Health, CFO,
  • Vystar Corporation, CFO,
  • Corautus Genetics, Deloitte

Ezra R. Lowe, Ph.D., Executive Director, Clinical and

Preclinical Pharmacology

  • Over 16 years of relevant experience in clinical pharmacology, drug metabolism, and pharmacokinetics
  • Broad base of experience working with various drug formats across a diverse array of therapeutic areas
  • Previous position was Senior Director, Clinical Pharmacology in Global R&D with Bausch Health Companies

Marla Mills-Wilson, Executive Director, Clinical Operations

  • Over 24 years of experience in program and project management, study operations, site management, and progression across Phase I to IV in a variety of therapeutic indications including liver-related diseases, oncology,

ophthalmology, and vaccines.

• Held previous positions with CymaBay Therapeutics and Intercept

5

Pharmaceuticals leading global studies

2021 Galectin Therapeutics | NASDAQ: GALT

For more information, see galectintherapeutics.com

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original document
  • Permalink

Disclaimer

Galectin Therapeutics Inc. published this content on 13 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 September 2021 21:31:02 UTC.